Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Le, Thuy Ai Huyen
- miRNA-141 as the Biomarker for Human Cancers
Abstract Views :281 |
PDF Views:176
Authors
Affiliations
1 University of Science, Vietnam National University, Ho Chi Minh City, VN
2 Department of Pharmaceutical and Medical Biotechnology, Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN
1 University of Science, Vietnam National University, Ho Chi Minh City, VN
2 Department of Pharmaceutical and Medical Biotechnology, Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 2 (2018), Pagination: 42-49Abstract
microRNA (miRNA) is considered to be a pivotal role in human numerous biological process, and their abnormal expression that functions either as tumor suppressor or oncogenes results in human cancer initiation and development microRNA-141 (miR-141), belonged to the miR-200 family, located at 12p13.31 and is also found to be abundantly expressed in many human cancers. Additionally, Prognostic and predictive miR-141 signatures have been defined for a variety of cancer types. This review summarized the biogenesis and processing of miRNA, as well as the roles of miR-141 in human cancer pathways, its targets and the potential utility of miR-141 as prognostic biomarkers.Keywords
Biomarker, Human Cancer, microRNA, microRNA-141.References
- Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6–7. Crossref PMid:16009126
- Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843–54. Crossref
- Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509–24. Crossref PMid:25027649
- Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9(2):102–14. Crossref PMid:18197166
- Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 24(7):e2156. Crossref PMid:27010857 PMCid:PMC4823963
- Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175–205. Crossref PMid:17506695
- Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857–66. Crossref PMid:17060945
- Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848–56. Crossref PMid:19884536 PMCid:PMC2793003
- Spence T, Bruce J, Yip KW, Liu FF. MicroRNAs in nasopharyngeal carcinoma. Chin Clin Oncol. 2016; 5(2):17. Crossref PMid:27121877
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281–97. Crossref
- Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 2010; 11(7):537–61. Crossref PMid:21532838 PMCid:PMC3048316
- Lin SL, Kim H, Ying SY. Intron-mediated RNA interference and microRNA (miRNA). Front Biosci. 2008; 13:2216–30. Crossref PMid:17981704
- Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004; 10(12):1957–66. Crossref PMid:15525708 PMCid:PMC1370684
- Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20):4051–60. Crossref PMid:15372072 PMCid:PMC524334
- Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126–39. Crossref PMid:19165215
- Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415–9. Crossref PMid:14508493
- Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes and Development. 2003; 17(24):3011–6. Crossref PMid:14681208 PMCid:PMC305252
- Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11(4):252–63. Crossref PMid:20216554
- Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009; 28(3-4):369–78. Crossref PMid:20012925
- Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, et al. microRNA-141 is involved in a nasopharyngeal carcinomarelated genes network. Carcinogenesis. 2010; 31(4):559–66. Crossref PMid:20053927
- Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 2014; 9(2):e88393. Crossref PMid:24551096 PMCid:PMC3923786
- Wu SM, Ai HW, Zhang DY, Han XQ, Pan Q, Luo FL, et al. MiR-141 targets ZEB2 to suppress HCC progression. Tumour Biol. 2014; 35(10):9993–7. Crossref PMid:25008569
- Lin L, Liang H, Wang Y, Yin X, Hu Y, Huang J, et al. microRNA-141 inhibits cell proliferation and invasion and promotes apoptosis by targeting hepatocyte nuclear factor-3β in hepatocellular carcinoma cells. BMC Cancer. 2014; 14:879. Crossref PMid:25425543 PMCid:PMC4289273
- Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci. 2010; 55(8):2365–72. Crossref PMid:19830559
- Ding L, Yu LL, Han N, Zhang BT. miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4. Oncol Lett. 2017; 13(3):1665–71. Crossref PMid:28454307 PMCid:PMC5403415
- Li JZ, Li J, Wang HQ, Li X, Wen B, Wang YJ. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017; 482(4):1381–6. Crossref PMid:27956179
- Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011; 128(3):608–16. Crossref PMid:20473869
- Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY, et al. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate. 2012; 72(14):1514–22. Crossref PMid:22314666
- Wang XL, Xie HY, Zhu CD, Zhu XF, Cao GX, Chen XH, et al. Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. Tumour Biol. 2015; 36(2):877–83. Crossref PMid:25304156
- Mahdavinezhad A, Mousavi-Bahar SH, Poorolajal J, Yadegarazari R, Jafari M, Shabab N, et al. Evaluation of miR141, miR-200c, miR-30b expression and clinicopathological features of bladder cancer. Int J Mol Cell Med. 2015; 4(1):32–9. PMid:25815280 PMCid:PMC4359703
- van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013; 32(36):4284–93. Crossref PMid:23045278
- Chen JL, Chen F, Zhang TT, Liu NF. Suppression of SIK1 by miR-141 in human ovarian cancer cell lines and tissues. Int J Mol Med. 2016; 37(6):1601–10. Crossref PMid:27081781
- Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011; 17(12):1627–35. Crossref PMid:22101765
- Li P, Xu T, Zhou X, Liao L, Pang G, Luo W, et al. Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: Involvement of ANP32E targeting. Cancer Med. 2017; 6(3):662–72. Crossref PMid:28220627 PMCid:PMC5345683
- Choi SK, Kim HS, Jin T, Hwang EH, Jung M, Moon WK. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A. BMC Cancer. 2016; 16:570. Crossref PMid:27484639 PMCid:PMC4969651
- Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, et al. Progesterone downregulation of miR141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015; 34(28):3676–87. Crossref PMid:25241899 PMCid:PMC4369481
- Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell–cell junctions. Nucleic Acids Research. 2005; 33(20):6566–78. Crossref PMid:16314317 PMCid:PMC1298926
- Tang K, Xu H. Prognostic value of meta-signature miRNAs in renal cell carcinoma: An integrated miRNA expression profiling analysis. Scientific Reports. 2015; 5:10272. Crossref PMid:25974855 PMCid:PMC4431463
- Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res. 2014; 20(10):2617–30. Crossref PMid:24647573
- Walworth NC. Cell-cycle checkpoint kinases: Checking in on the cell cycle. Curr Opin Cell Biol. 2000; 12(6):697–704. Crossref
- Tricoli JV, Jacobson JW. MicroRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007; 67(10):4553–5. Crossref PMid:17510380
- Macha MA, Seshacharyulu P, Krishn SR, Pai P, Rachagani S, Jain M, et al. MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des.2014; 20(33):5287–97. Crossref PMid:24479799 PMCid:PMC4113605
- Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016; 13(12):734–52. Crossref PMid:27804986
- Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654–9. Crossref PMid:17486113
- Zheng H, Liu JY, Song FJ, Chen KX. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biology and Medicine. 2013; 10(3):123–30. PMid:24379986 PMCid:PMC3860338
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513–8. Crossref PMid:18663219 PMCid:PMC2492472
- Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011; 9(1):39–45. Crossref PMid:21723797
- Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, LorenzoPati-o MJ, Haz-Conde M, et al. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 2015; 15:297. Crossref PMid:25885099 PMCid:PMC4405843
- Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011; 6(3):e17745. Crossref PMid:21445232 PMCid:PMC3060165
- Characteristic of ZMYND10 Gene’s Promoter Hypermethylation in Nasopharyngeal Carcinoma Biopsies from Vietnamese Patients
Abstract Views :240 |
PDF Views:130
Authors
Affiliations
1 University of Science, Vietnam National University, Ho Chi Minh City, VN
2 Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN
1 University of Science, Vietnam National University, Ho Chi Minh City, VN
2 Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 3 (2018), Pagination: 69-74Abstract
Silencing of tumor suppressor gene, which caused by the DNA hypermethylation, an epigenetic modification, has been reported to be involved in human various cancers, including nasopharyngeal carcinoma. The aims of this study were to identify and evaluate the hypermethylation frequency of the ZMYND10 promoter, which located at 3p21.3, in nasopharyngeal biopsies from Vietnamese patients by Nested Methylation Specific PCR (Nested MSP). In current study, ninety tumor biopsies and ninety healthy samples, which were obtained from Cho Ray hospital, were enrolled into study. As the results, the hypermethylation frequency of ZMYND10 gene promoter was more frequent in tumor biopsies. In detail, the hypermethylation frequency of ZMYND10 gene promoter were 81.11% (73 of 90 samples), and 45.56% (41 of 90 samples) for in NPC biopsies and non-cancerous specimens. A trend toward positive association was found between hypermethylation of ZMYND10 gene and nasopharyngeal carcinoma (p < 0.0007). Additionally, the high Odds ratio (OR) and Relative risk were observed (OR = 5.13, RR = 2.49) (p <0.0001). In conclusion, our data suggested that the hypermethylation of ZMYND10 gene promoter is a significant in nasopharyngeal carcinoma in Vietnamese patients.Keywords
Hypermethylation, Nasopharyngeal Carcinoma, Tumor Suppressor Gene, ZMYND10.References
- Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, Lin ZX, Ng MH, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet. 1990; 335(8686):371–4. https:// doi.org/10.1016/0140-6736(90)90206-K
- Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765–77. https://doi.org/10.1158/10559965.EPI-06-0353 PMid:17035381
- GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
- Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: A review. Epidemiol Rev. 1993; 15(2):466–85. https://doi.org/10.1093/oxfordjournals.epirev.a036130 PMid:8174667
- Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821–6. https://doi.org/10.1073/pnas.93.18.9821 PMid:8790415 PMCid:PMC38513
- Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001; 134(7):573–86. https:// doi.org/10.7326/0003-4819-134-7-200104030-00011 PMid:11281740
- Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clin Chim Acta. 2012; 413(7-8):795–802. https://doi.org/10.1016/j.cca.2012.01.018 PMid:22296674
- Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res. 1997; 71:27–92. https://doi.org/10.1016/S0065-230X(08)60096-2
- Ji L, Minna JD, Roth JA. 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol. 2005; 1(1):79–92. https://doi.org/10.1517/14796694.1.1.79 PMid:16555978
- Cheng Y, Ho RL, Chan KC, Kan R, Tung E, Lung HL, et al. Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma. Oncogene. 2015; 34(32):4219–28. https://doi.org/10.1038/onc.2014.353 PMid:25347745 PMCid:PMC4761643
- Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007; 26(52):7283–301. https://doi.org/10.1038/sj.onc.1210547 PMid:17533367
- Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, et al. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer. 2003; 106(1):60–5. https://doi.org/10.1002/ijc.11166 PMid:12794757
- Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, et al. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene. 2004; 23(27):4793–806. https://doi.org/10.1038/ sj.onc.1207632 PMid:15122337
- Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res. 2008; 28(4B):2161–7. PMid:18751390
- Epstein JB, Jones CK. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg Oral Med Oral Pathol. 1993; 75(1):32–6. https://doi.org/10.1016/0030-4220(93)90402-P
- Hao SP, Tsang NM, Chang KP, Ueng SH. Molecular diagnosis of nasopharyngeal carcinoma: detecting LMP-1 and EBNA by nasopharyngeal swab. Otolaryngol Head Neck Surg. 2004; 131(5):651–4. https://doi.org/10.1016/j.otohns.2004.04.013 PMid:15523443
- Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12(6):451–62. https://doi.org/10.1016/ S1044579X02000883
- Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60(21):5954–8. PMid:11085511
- Zhang X, Liu H, Li B, uang P, Shao J, He Z. Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter. BMC Cancer. 2012; 12:267. https://doi.org/10.1186/1471-2407-12-267 PMid:22727408 PMCid:PMC3585814
- Study of Mir-141 and its Potential Targeted mRNA PTEN Expression in Nasopharyngeal Carcinoma:From in Silico to Initial Experiment Analysis
Abstract Views :189 |
PDF Views:138
Authors
Affiliations
1 University of Science, Vietnam National University Ho Chi Minh City, VN
2 Ho Chi Minh City Open University, Ho Chi Minh City, VN
1 University of Science, Vietnam National University Ho Chi Minh City, VN
2 Ho Chi Minh City Open University, Ho Chi Minh City, VN
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 3 (2018), Pagination: 75-83Abstract
Recently, accumulating evidences indicated that microRNA-141 (miR-141) is associated with NPC due to their abilities to affect the expression of genes that modulate tumorigenesis. Unfortunately, there is still limited publication about miR-141 expression in Vietnamese nasopharyngeal cancer patients. In this study, we adopted bioinformatics tools, such as Pictar, Target Scan, miRDB, etc. to predict its target gene. As the results, PTEN (phosphatase and tensin homolog gene), acts oncogenic role associated with biological processes lead to the nasopharyngeal carcinogenesis, was identified as the direct target of miR-141. Experimentally, we reported the evaluation of miR-141 and PTEN expression in NPC biopsy samples and non-cancerous swab samples. The present study demonstrated that miR-141 was upregulated 9.38 times, and PTEN expression was significantly lowered in NPC biopsy samples compared to non-cancerous epithelial swab samples. Our finding demonstrated that the miR-141 was upregulated and PTEN was down regulated in NPC biopsy samples. In the upcoming research, a larger clinical sample size from patients at each stage of the NPC will be performed to understand the expression pattern of the miR-141 and PTEN for further applied in early diagnosis and prognosis as well as therapeutic of NPC.Keywords
miR-141, Nasopharyngeal Carcinoma, PTEN.References
- GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012; 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
- Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of Nasopharynx cancer in Asia. Osong Public Health and Research Perspectives. 2016; 7(6):360–72. https://doi.org/10.1016/j.phrp.2016.11.002 PMid:28053841 PMCid:PMC5194228
- Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6–7. https://doi.org/10.1016/j.cell.2005.06.036 PMid:16009126
- Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009; 136(2):215–33. https://doi.org/10.1016/j.cell.2009.01.002 PMid:19167326 PMCid:PMC3794896
- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522–31. https://doi.org/10.1038/nrg1379 PMid:15211354
- Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175–205. https://doi.org/10.1146/ annurev.cellbio.23.090506.123406 PMid:17506695
- Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857–66. https://doi.org/10.1038/nrc1997 PMid:17060945
- Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509–24. https://doi.org/10.1038/nrm3838 PMid:25027649
- Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302(1):1–12. https://doi.org/10.1016/j.ydbio.2006.08.028
- Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. https://doi.org/10.1016/j.molmed.2014.06.005 PMid:25027972
- Kala R, Peek GW, Hardy TM, Tollefsbol TO. MicroRNAs: an emerging science in cancer epigenetics. J Clin Bioinforma. 2013; 3(1):6. https://doi.org/10.1186/2043-9113-3-6 PMid:23497588 PMCid:PMC3608239
- Lee KT, Tan JK, Lam AK, Gan SY. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit Rev Oncol Hematol. 2016; 103:1–9. https://doi.org/10.1016/j.critrevonc.2016.04.006 PMid:27179594
- Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, et al. microRNA-141 is involved in a nasopharyngeal carcinomarelated genes network. Carcinogenesis. 2010; 31(4):559–66. https://doi.org/10.1093/carcin/bgp335 PMid:20053927
- Zuo QF, Zhang R, Li BS, Zhao YL, Zhuang Y, Yu T, et al. MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. Cell Death Dis. 2015; 6:e1623. https://doi.org/10.1038/cddis.2014.573
- Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/ AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 7:e2156. https://doi.org/10.1038/cddis.2016.64 PMid:27010857 PMCid:PMC4823963
- Liu Y, Zhao R, Wei Y, Li M, Wang H, Niu W, et al. BRD7 expression and c-Myc activation forms a double-negative feedback loop that controls the cell proliferation and tumor growth of nasopharyngeal carcinoma by targeting oncogenic miR-141. J Exp Clin Cancer Res. 2018; 37(1):64. https://doi.org/10.1186/s13046-018-0734-2 PMid:29559001 PMCid:PMC5859396
- Lao DT, Truong KP, Le HAT. miRNA-141 as the Biomarker for Human Cancers. AJPRHC. 2018; 10(2):42-9. https:// doi.org/10.18311/ajprhc/2018/21486
- Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999; 59(8):1820–4. PMid:10213484
- Li A, Zhang XS, Jiang JH, Wang HH, Liu XQ, Pan ZG, et al. Transcriptional expression of RPMS1 in nasopharyngeal carcinoma and its oncogenic potential. Cell Cycle. 2005; 4(2):304–9. https://doi.org/10.4161/cc.4.2.1416 PMid:15725729
- Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999; 96(11):6199–204. https://doi.org/10.1073/ pnas.96.11.6199 PMid:10339565 PMCid:PMC26859
- Mahimainathan L, Choudhury GG. Inactivation of plateletderived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem. 2004; 279(15):15258–68. https:// doi.org/10.1074/jbc.M314328200 PMid:14718524
- Shinde SR, Maddika S. PTEN modulates EGFR late endocytic trafficking and degradation by dephosphorylating Rab7. Nat Commun. 2016; 7:10689. https://doi.org/10.1038/ ncomms10689 PMid:26869029 PMCid:PMC4754336
- Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016; 6(2):202–16. https:// doi.org/10.1158/2159-8290.CD-15-0283 PMid:26645196 PMCid:PMC4744499
- Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem. 2009; 284(18):11755–9. https://doi.org/10.1074/jbc.R800071200 PMid:19117948 PMCid:PMC2673242
- Maier D, Jones G, Li X, Schönthal AH, Gratzl O, Van Meir EG, et al. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res. 1999; 59(21):5479–82. PMid:10554022
- Leslie NR, Yang X, Downes CP, Weijer CJ. PtdIns(3,4,5) P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol. 2007; 17(2):115–25. https://doi.org/10.1016/j.cub.2006.12.026 PMid:17240336 PMCid:PMC1885949
- Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle. 2005; 4(7):927–9. https://doi.org/10.4161/cc.4.7.1795 PMid:15970699
- Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007; 128(1):157–70. https:// doi.org/10.1016/j.cell.2006.11.042 PMid:17218262
- Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 1998; 58(24):5667–72. PMid:9865719
- Xu Z, Stokoe D, Kane LP, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Differ. 2002; 13(7):285–96. PMid:12133897
- Pal A, Barber TM, Van de Bunt M, Rudge SA, Zhang Q, Lachlan KL, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012; 367(11):1002–11. https://doi.org/10.1056/ NEJMoa1113966 PMid:22970944 PMCid:PMC4072504
- Ortega-Molina A, Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab. 2013; 24(4):184–9. https://doi.org/10.1016/j.tem.2012.11.002 PMid:23245767 PMCid:PMC3836169
- Markopoulos GS, Roupakia E, Tokamani M, Chavdoula E, Hatziapostolou M, Polytarchou C, et al. A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol (Dordr). 2017; 40(4):303–39. https://doi.org/10.1007/s13402-017-0341-9 PMid:28748501
- Chen P, Guo X, Zhou H, Zhang W, Zeng Z, Liao Q, et al. SPLUNC1 regulates cell progression and apoptosis through the miR-141-PTEN/p27 Pathway, but is hindered by LMP1. Samant R, editor. PLoS ONE. 2013; 8(3):e56929.
- First Record of Identification of RPMS1 Gene Variations in Vietnamese Nasopharyngeal Carcinoma Patients
Abstract Views :256 |
PDF Views:196
Authors
Affiliations
1 Ho Chi Minh City Open University, 97 Vo Van Tan Str., Ward 6, District 3 Ho Chi Minh City − 700000, VN
2 University of Science, Vietnam National University, Ho Chi Minh City, 227 Nguyen Van Cu Str., Ward 4, District 5 − 700000, VN
1 Ho Chi Minh City Open University, 97 Vo Van Tan Str., Ward 6, District 3 Ho Chi Minh City − 700000, VN
2 University of Science, Vietnam National University, Ho Chi Minh City, 227 Nguyen Van Cu Str., Ward 4, District 5 − 700000, VN
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 4 (2018), Pagination: 97-103Abstract
Epstein-Barr Virus (EBV) infection and EBV genes’ variation are considered as the etiological factors contributed to Naso- Pharyngeal Carcinoma (NPC). In the latent EBV stage, not only the latent membrane proteins but also RPMS1 expression has been confirmed in all EBV-associated tumors. In Vietnam, an Asian country with the high incidence, mortality rate of NPC, had limit research on the RMPS1 gene variation. Therefore, the objects of current study were to identify the pattern of RMPS1 variations in Vietnamese NPC patients for its value further applied in NPC patients. In this study, thirty NPC biopsy samples and thirty non-cancerous swab specimens were collected from local patients, analyzed by PCR, sequencing and compared to previous B95-8 sequence. As the results, the strongly association between the detection of RPSM1 gene and NPC incidence in Vietnamese NPC patients was determined. Additionally, the RMPS1 gene variants, including wild-type, RMPS1-B, RMPS1-C, RMPS1-C*, were identified. Among them, RMPS1-C/C* was preferential in Vietnamese nasopharyngeal cancer. In conclusion, those data is the first dataset on the polymorphism in the RPMS1 gene in Vietnamese NPC patients, and could be utilized as a promising biomarker for prognosis, diagnosis and therapy for NPC based on the EBV gene variations.Keywords
Nasopharyngeal Carcinoma, RPMS1, Variations.References
- Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet. 1990; 335(8686):371−4. https://doi.org/10.1016/0140-6736(90)90206-K.
- Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765−77. https://doi.org/10.1158/1055-9965.EPI-06-0353. PMid:17035381.
- GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
- Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014; 50(5):330−38. https://doi.org/10.1016/j.oraloncology.2014.02.006. PMid: 24630258.
- Lao TD, Truong PK, Le THA. miRNA-141 as the Biomarker for Human Cancers. AJPRHC. 2018; 10(2):42−49. https://doi.org/10.18311/ajprhc/2018/21486.
- Lao TD, Nguyen DH, Le THA. Study of mir-141 and its Potential Targeted mRNA PTEN Expression in Nasopharyngeal Carcinoma: From in Silico to Initial Experiment Analysis. AJPRHC. 2018; 10(3):66−74. https://doi.org/10.18311/ajprhc/2018/22341.
- Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH, Le THA. miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. Braz Oral Res. 2018; 32:e126. https://doi.org/10.1590/18073107bor-2018.vol32.0126.
- Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev. 1993; 15(2):466−85. https://doi.org/10.1093/oxfordjournals.epirev.a036130. PMid: 8174667.
- Wu S, Liu W, Li H, Zhao Z, Yang Y, Xiao H, et al. Conservation and polymorphism of EBV RPMS1 gene in EBV-associated tumors and healthy individuals from endemic and non-endemic nasopharyngeal carcinoma areas in China. Virus Res. 2018; 250:75−80. https://doi.org/10.1016/j.virusres.2018.04.009. PMid: 29665370.
- Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Molecular Pathology. 2000; 53(5):238−47. https://doi.org/10.1136/mp.53.5.238. PMid:11091847, PMCid: PMC1186976.
- Marquitz AR, Raab-Traub N. The role of miRNAs and EBV BARTs in NPC. Semin Cancer Biol. 2012; 22(2):166−72. https://doi.org/10.1016/j.semcancer.2011.12.001. PMid: 22178394, PMCid: PMC3340885.
- Gilligan KJ, Rajadurai P, Lin JC, Busson P, Abdel-Hamid M, Prasad U, et al. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol. 1991; 65(11):6252−59.
- Smith PR, de Jesus O, Turner D, Hollyoake M, Karstegl CE, Griffin BE, Karran L, Wang Y, Hayward SD, Farrell PJ. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J. Virol. 2000; 74(7):3082−92. https://doi.org/10.1128/JVI.74.7.3082-3092.2000. PMid: 10708423, PMCid: PMC111807.
- Hui KF, Chan TF, Yang W, Shen JJ, Lam KP, Kwok H, Sham PC, Tsao SW, Kwong DL, Lung ML, Chiang AKS. High risk Epstein-Barr virus variants characterized by distinct polymorphisms in the EBER locus are strongly associated with nasopharyngeal carcinoma. Int. J. Cancer. 2018; [Epub ahead of print]. https://doi.org/10.1002/ijc.32049.
- Chao M, Wang HN, Lu YJ, Chang YS, Yu JS. The V-val subtype Epstein-Barr virus nuclear antigen 1 promotes cell survival after serum withdrawal. Oncol Rep. 2015; 33(2):958−66. https://doi.org/10.3892/or.2014.3625. PMid: 25434292.
- Feng FT, Cui Q, Liu WS, Guo YM, Feng QS, Chen LZ, Xu M, Luo B, Li DJ, Hu LF, Middeldorp JM, Ramayanti O, Tao Q, Cao SM, Jia WH, Bei JX, Zeng YX. A single nucleotide polymorphism in the Epstein-Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma. Chin. J. Cancer. 2015; 34(12):563−72. https://doi.org/10.1186/s40880-015-0073-z.
- Lao TD, Nguyen DH, Nguyen TM, Le TAH. Molecular Screening for Epstein-Barr virus (EBV): Detection of Genomic EBNA-1, EBNA-2, LMP-1, LMP-2 Among Vietnamese Patients with Nasopharyngeal Brush Samples. Asian Pac. J. Cancer Prev. 2017; 18(6):1675−1679.
- Cui Q, Feng FT, Xu M, Liu WS, Yao YY, Xie SH, Li XZ, Ye ZL, Feng QS, Chen LZ, Bei JX, Feng L, Huang QH, Jia WH, Cao SM, Chang ET, Ye W, Adami HO, Zeng YX. Nasopharyngeal carcinoma risk prediction via salivary detection of host and Epstein-Barr virus genetic variants. Oncotarget. 2016; 8(56):95066−74. https://doi.org/10.18632/oncotarget.11144.
- Yap YY, Hassan S, Chan M, Choo PK, Ravichandran M. Epstein-Barr virus DNA detection in the diagnosis of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2007; 136(6):986−91. https://doi.org/10.1016/j.otohns.2006.11.027. PMid: 17547993.
- Zhang J, Chen H, Weinmaster G, Hayward SD. EpsteinBarr virus BamHi-a rightward transcript-encoded RPMS protein interacts with the CBF1-associated corepressor CIR to negatively regulate the activity of EBNA2 and NotchIC. J. Virol. 2001; 75(6):2946−56. https://doi.org/10.1128/JVI.75.6.2946-2956.2001. PMid: 11222720, PMCid: PMC115921.
- Development of Stem-Loop Real-Time PCR Technique for miRNA-141 Expression Analysis in Nasopharyngeal Carcinoma
Abstract Views :206 |
PDF Views:180
Authors
Affiliations
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ward Co Giang, District 1, HCMC, Ho Chi Minh City, VN
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ward Co Giang, District 1, HCMC, Ho Chi Minh City, VN
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 11, No 2-4 (2019), Pagination: 30-36Abstract
Background: The deregulation of miRNA-141 (miR-141) has been reported to be involved in development and progression of many various types of human cancers. Previously, it has been demonstrated that miR-141 served as the oncogenic role in nasopharyngeal carcinoma in different countries. However, in Vietnam, to our knowledge, there are limit study of the types of evaluation of miR-141 expression. Objective: For the aims to find out the novel diagnosis strategies and promising therapies for many human based on the expression of miRNA, we the stem-loop qRT-PCR method described here is to detect mature miRNA-141 in a fast, specific, accurate, and reliable manner. Methods: StL-miR-141, known as stem-loop RT primer is applied for Reversed transcriptase assay, followed by Real-time PCR assay using StL-F, STL-R primer and SYBR-Green. Results: Experimentally, this method was applied in detection of miR-141 in Vietnamese NPC biopsy samples, as the results, 5 of six NPC were positive to miR-141 expression. Moreover, the electrophoresis analysis was performed to evaluate the Specificity. The assay has shown high specific for miR-141 detection. Conclusion: We successfully designed the stem-loop RT primer, StL-F, STL-R primer, might be used as a rapid, simple method for the detectionwith a wider scope to apply this method onto the Vietnamese population.Keywords
miRNAs, miR-141, Stem-Loop RT PCR.References
- GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
- Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia. Osong Public Health Res. Perspect. 2016; 7(6):360-72. https://doi.org/10.1016/j.phrp.2016.11.002. PMid: 28053841, PMCid: PMC5194228.
- Epstein JB, Jones CK. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg. Oral. Med. Oral. Pathol. 1993; 75(1):32-36. https://doi.org/10.1016/00304220(93)90402-P.
- Hao SP, Tsang NM, Chang KP, Ueng SH. Molecular diagnosis of nasopharyngeal carcinoma: Detecting LMP-1 and EBNA by nasopharyngeal swab. Otolaryngol Head Neck Surg. 2004; 131(5):651-54. https://doi.org/10.1016/j.otohns.2004.04.013. PMid: 15523443.
- Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 7:e2156. https://doi.org/10.1038/cddis.2016.64. PMid: 27010857, PMCid: PMC4823963.
- Lee RC, Feinbaum RL, Ambros V. The C. elegansheterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. https://doi.org/10.1016/0092-8674(93)90529-Y.
- Ha M, Kim VN. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell. Biol. 2014; 15(8):509-24. https://doi.org/10.1038/nrm3838. PMid: 25027649.
- Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. https://doi.org/10.1016/S0092-8674(04)00045-5.
- Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer. 2006; 6(11):857-66. https://doi.org/10.1038/nrc1997. PMid: 17060945.
- Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: A typical multifunctional microRNA. Biochim. Biophys. Acta. Biochim. Biophys. Acta. 2009; 1792(6):497-505. https://doi.org/10.1016/j.bbadis.2009.02.013. PMid: 19268705.
- Macfarlane LA, Murphy PR. Micro RNA: Biogenesis, function and role in cancer. Curr. Genomics. 2010; 11(7):537-61. https://doi.org/10.2174/138920210793175895. PMid: 21532838, PMCid: PMC3048316.
- Du ZM, Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY, et al. Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and down regulates a negative prognostic marker JMJD1A. PLoS One. 2011; 6:e19137. https://doi.org/10.1371/journal.pone.0019137. PMid: 21541331, PMCid: PMC3082546.
- Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 2011; 38(6):724-33. https://doi.org/10.1053/j.seminoncol.2011.08.006. PMid: 22082758.
- Amin M, Lam AK. Current perspectives of mi-RNA in oesophageal adenocarcinoma: Roles in predicting carcinogenesis, progression and values in clinical management. Exp. Mol. Pathol. 2015; 98(3):411-18. https://doi.org/10.1016/j.yexmp.2015.03.002. PMid: 25746664.
- Lee KT, Tan JK, Lam AK, Gan SY. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit. Rev. Oncol. Hematol. 2016; 103:1-9. https://doi.org/10.1016/j.critrevonc.2016.04.006. PMid:27179594.
- Lao DT, Truong KP, Le HAT.miRNA-141 as the Biomarker for Human Cancers. JPRHC. 2018; 10:42-49. https://doi.org/10.18311/ajprhc/2018/21486.
- Li G, Huang M, Cai Y, Ke Y, Yang Y, Sun X. miR 141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression. Mol. Med. Rep. 2018(2); 18:1395-1404. https://doi.org/10.3892/ mmr.2018.9108.
- Lin L, Liang H, Wang Y, Yin X, Hu Y, Huang J, et al. microRNA-141 inhibits cell proliferation and invasion and promotes apoptosis by targeting hepatocyte nuclear factor-3β in hepatocellular carcinoma cells. BMC cancer. 2014; 14:879. https://doi.org/10.1186/1471-2407-14-879. PMid: 25425543, PMCid: PMC4289273.
- Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122:6-7. https://doi.org/10.1016/j.cell.2005.06.036. PMid: 16009126.
- Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stemloop RT-PCR. Nucleic Acids Res. 2005; 33(20):e179. https://doi.org/10.1093/nar/gni178. PMid: 16314309, PMCid: PMC1292995.
- The Prognosis Value of CDH-1 Methylation-The Epigenetic Biomarker in Nasopharyngeal Carcinoma:Systematic Review and Meta-Analysis
Abstract Views :188 |
PDF Views:168
Authors
Affiliations
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, VN
2 Faculty of Biology and Biotechnology, Ho Chi Minh City University of Science, Hồ Chí Minh − 700000, VN
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, VN
2 Faculty of Biology and Biotechnology, Ho Chi Minh City University of Science, Hồ Chí Minh − 700000, VN
Source
Asian Journal of Pharmaceutical Research and Health Care, Vol 11, No 2-4 (2019), Pagination: 68-74Abstract
Background: The phenome of CDH-1 gene methylation has been reported to be associated with the nasopharyngeal tumorigenesis. Objective: Aiming to evaluate the association between the CDH-1 gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for nasopharyngeal cancer risk based on meta-analysis. Materials and Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds Ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effects models. Results: Total of 12 studies, including 500 samples from NPC patients and 201 samples from non-cancerous samples, were enrolled in current study. Overall, the frequency of CDH-1 gene methylation were 48.50% and 3.09% in the case and control group, respectively. The association between the CDH-1 gene methylation and risk of NPC was also confirmed by calculating OR value of 15.33 (95% CI = 7.82-30.06), based on the fix-effects model. Additionally, the significant association was also found between the methylation of CDH-1 gene and subgroups. Conclusion: this meta-analysis provides scientific evidences to suggest the CDH-1 methylation was the potential biomarker for risk of NPC.Keywords
CDH-1, Epigenetic Biomarker, Nasopharyngeal carcinoma, Meta-Analysis.References
- Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet 1990; 335(8686):371-74. https://doi.org/10.1016/01406736(90)90206-K
- Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Res. 2009; 143(2):209-21. https://doi.org/10.1016/j.virusres.2009.07.005. PMid: 19596032, PMCid: PMC2731007.
- Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of Nasopharynx Cancer in Asia. Osong. Public Health Res. Perspect. 2016; 7(6):360-72. https:// doi.org/10.1016/j.phrp.2016.11.002. PMid: 28053841, PMCid: PMC5194228.
- Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH, Le THA. miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. Braz. Oral. Res. 2018a; 32:e126. https://doi.org/10.1590/1807-3107bor-2018.vol32.0126. PMid: 30569973.
- Lao TD, Nguyen DH, Le THA. Study of mir-141 and its potential targeted mRNA PTEN expression in Nasopharyngeal Carcinoma: From in Silico to initial experiment analysis. AJPRHC. 2018b; 10(3):66-74. https://doi.org/10.18311/ajprhc/2018/22341.
- Lao TD, Le THA. Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: An update report. Adv. Life Sci. 2020; 7(2):86-90.
- Wang LH, Wu CF, Rajasekaran N, Shin YK. Loss of tumor suppressor gene function in human cancer: An Overview. Cell Physiol. Biochem. 2018; 51(6):2647-93. https://doi.org/10.1159/000495956. PMid: 30562755.
- Goodwin M, Yap AS. Classical cadherin adhesion molecules: Coordinating cell adhesion, signaling and the cytoskeleton. J. Mol. Histol. 2004; 35:839-44. https://doi.org/10.1007/s10735004-1833-2. PMid: 15609097.
- Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene. 2008; 27(55):6920-29. https://doi.org/10.1038/ onc.2008.343. PMid: 19029934, PMCid: PMC2745643.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097. PMid: 19621072, PMCid: PMC2707599.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21(11):1539-58. https://doi.org/10.1002/sim.1186. PMid: 12111919.
- DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat. Med. 1996; 15(12):1237-48. https://doi.org/10.1002/(SICI)1097-0258(19960630)15:12<1237::AIDSIM301> 3.0.CO;2-N.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60.https://doi.org/10.1136/bmj.327.7414.557 PMid: 12958120, PMCid: PMC192859.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088101. https://doi.org/10.2307/2533446. PMid: 7786990.
- Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. https://doi.org/10.1136/bmj.315.7109.629. PMid: 9310563, PMCid: PMC2127453.
- Chang HW, Chan A, Kwong DLW, Wei WI, Sham JST, Yuen APW. Evaluation of Hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int. J. Cancer. 2003; 105:851-55. https://doi.org/10.1002/ijc.11162. PMid: 12767073.
- Wong TS, Tang KC, Kwong DLW, Sham JST, Wei WI, Kwong YL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. International Journal of Oncology. 2003; 22:869-74. https://doi.org/10.3892/ijo.22.4.869.
- Tsao SW, Liu Y, Wang XX, Yuen PW, Leung SY, Yuen ST, et al. The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. European Journal of Cancer. 2003; 39:524-31. https://doi.org/10.1016/S0959-8049(02)00494-X.
- Li Z, Lin SX, Liang YJ. Influence of E-cadherin promoter methylation and mutation of beta-catenin on invasion and metastasis of nasopharyngeal carcinoma cells. Europe PMC. 2003; 25(3):238-42.
- Li Z, Lin S, Liang YJ. Detection of gene promoter methylation and mRNA, protein expression levels of E-cadherin in nasopharyngeal carcinoma. Springer. 2003; 32(1):25.30. PMID:12760799
- Wong TS, Kwong DLW, Sham JST, Wei WI, Kwong YL, Yuen APW. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clinical Cancer Research. 2004; 10:2401-06. https://doi.org/10.1158/10780432.CCR-03-0139. PMid: 15073117.
- Li Z, Ren Y, Lin SX, Liang YJ, Liang HZ. Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma. Europe PMC. 2004; 117(8):1232-39.
- Tan SH, Ida H, Goh BC, Hsieh W, Loh M, Ito Y. Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. Anticancer Research. 2006; 26:4287-92.
- Niemhom S, Kitazawa S, Kitazawa R, Maeda S, Leopairat J. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. Cancer Detection and Prevention. 2008; 32:127-34. https://doi.org/10.1016/j.cdp.2008.05.005. PMid:18632221.
- Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-Cadherin gene promoters in nasopharyngeal carcinoma biopsies from tunisian patients. Anticancer Research. 2008; 28:2161-68.
- Ran Y, Wu S, You Y. Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J. Biochem. 2011; 149(1):49-54. https://doi.org/10.1093/jb/mvq128.PMid: 21059597.
- Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clinica. Chimica. Acta. 2012; 413:795-802. https://doi.org/10.1016/j.cca.2012.01.018. PMid: 22296674.
- Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin. J. Cancer. 2011; 30(4):231-39. https://doi.org/10.5732/cjc.011.10080 PMid: 21439244, PMCid: PMC4013349.
- Jiang W, Cai R, Chen QQ. DNA Methylation biomarkers for nasopharyngeal carcinoma: Diagnostic and prognostic tools. Asian Pac. J. Cancer Prev. 2015; 16(18):8059-65. https://doi.org/10.7314/APJCP.2015.16.18.8059. PMid: 26745039.
- Semb H, Christofori G. The tumor-suppressor functions of E-cadherin. Am. J. Hum. Genet. 1998; 63(6):1588-93. https://doi.org/10.1086/302173. PMid: 9837810, PMCid: PMC1377629.
- Pećina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003; 3(1):17. https://doi.org/10.1186/1475-2867-3-17 PMid: 14613514, PMCid: PMC270068.
- Huang Z, Bassil CF, Murphy SK. Methylation-specific PCR. Methods Mol. Biol. 2013; 1049:75-82. https://doi.org/10.1007/978-1-62703-547-7_7. PMid: 23913210.
- Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M. DAPK1 promoter Methylation and cervical cancer risk: A systematic review and a meta-analysis. PLoS One. 2015; 10(8):e0135078. https:// doi.org/10.1371/journal.pone.0135078. PMid: 26267895, PMCid: PMC4534406.